Ofranergene Obadenovec/Paclitaxel Combo Misses Survival End Points in Platinum-Resistant Ovarian Cancer

The combination of ofranergene obadenovec (ofra-vec; VB-111) and paclitaxel failed to elicit a statistically significant improvement in progression-free survival (PFS) or overall survival (OS) compared with paclitaxel alone in patients with platinum-resistant ovarian cancer, missing the coprimary end points of the study, according to topline findings from the phase 3 OVAL trial (NCT03398655).¹

The results showed that the median PFS was 5.29 months with the combination vs 5.36 months with paclitaxel alone (HR, 1.03). The interim OS analysis was also not significantly different between the study arms, with a median OS of 13.37 months and 13.14 months, respectively (HR, 0.97).

“Given the urgent unmet need for those fighting platinum-resistant ovarian cancer, we are deeply disappointed that the top-line data indicate that ofra-vec did not improve progression-free survival or overall survival,” Dror Harats, MD, chief executive officer of VBL Therapeutics, said in a news release. “Based on this outcome, we plan to discontinue the OVAL trial and will review the data from our ongoing phase 2 trials in metastatic colorectal cancer and recurrent glioblastoma multiforme to determine next steps with the ofra-vec program. We extend our deepest gratitude to all the patients, families and healthcare professionals who participated in this trial.”

Ofra-vec is a targeted anticancer viral gene therapy designed to use a dual mechanism to target several solid tumors, including ovarian cancer. The mechanism combines the inhibition of tumor vasculature with an antitumor immune response.

In April 2022, the FDA granted a fast track designation to the agent for use as a potential therapeutic option in patients with platinum-resistant ovarian cancer.² Prior data from a phase 1/2 trial (NCT01711970) demonstrated that the combination of ofra-vec and paclitaxel was safe and effective in this patient population.^3,4

OVAL was an international, phase 3, randomized, double-blind, placebo-controlled, trial that compared the combination of ofra-vec and paclitaxel with placebo plus paclitaxel in 409 adult patients with recurrent platinum-resistant ovarian cancer.

Eligible patients were at least 18 years of age with histologically confirmed epithelial ovarian cancer and platinum resistance. Additionally, patients had to have an ECOG performance status of 0 or 1, measurable disease per RECIST v1.1 criteria that required chemotherapy treatment, and acceptable hematologic function.⁵

Patients were randomly assigned to ofra-vec plus paclitaxel or placebo plus paclitaxel. Investigators administered itravenous (IV) ofra-vec at 1 x 10¹³ viral particles every 2 months. Both treatment arms received 80 mg/m² of IV paclitaxel weekly.

The primary end points of the trial were OS and PFS. Secondary end points included combined CA-125 and RECIST v1.1 response, CA-125 response, objective response rate per RECIST v1.1 criteria, and OS100 for a sensitivity analysis of OS.

In March 2020, OVAL was allowed to continue without modification after an independent data safety monitoring committee (DMSC) determined that the combination hit the prespecified benchmark of an absolute percentage advantage of at least 10% in CA-125 response vs placebo plus paclitaxel.⁶

Specifically, the combination led to a CA-125 response rate of 53% in the first 60 evaluable patients across both treatment arms. The response rate in the investigative arm, assuming a balanced randomization, was 58% or higher. Additionally, in those with post-dosing fever, a known marker for VB-111, the reported response rate with the regimen was 69%.

Subsequently, in August 2020, the DMSC evaluated the unblinded OS data collected on the first 100 participants who underwent randomization and had at least 3 months of follow up. Based on these findings, they unanimously recommended that the trial to continue.⁷ As of November 16, 2020, a high response rate of over 50% in evaluable patients was maintained with approximately 200 patients enrolled.

The following year, in February 2021, the trial received another green light to continue, after a review of unblinded data from 370 randomized patients did not reveal any safety issues.⁸

References

1. VBL Therapeutics announces top-line data from phase 3 OVAL trial of ofra-vec in patients with platinum-resistant ovarian cancer. News release. VBL Therapeutics. July 19, 2022. Accessed July 20, 2022. https://bit.ly/3zlJWAo
2. VBL Therapeutics receives FDA fast track designation for ofra-vec for the treatment of platinum-resistant ovarian cancer. News release. VBL Therapeutics. April 26, 2022. Accessed July 20, 2022. https://bit.ly/3Lm3mZA
3. VBL final phase 1/2 study results presented at ASCO demonstrate VB-111 dose dependent Increase in overall survival and 58% CA-125 response rate in platinum-resistant ovarian cancer. News release. VBL Therapeutics. June 3, 2019. Accessed July 20, 2022. https://bit.ly/3axNS2x
4. Cohen YC, Berlin ST, Birrer MJ, et al. Ofranergene obadenovec (VB-111) in platinum resistant ovarian cancer: association of favorable response rates in a phase I/II study with an immunotherapeutic effect. J Clin Oncol. 2019;37(suppl 15):5542. doi:10.1200/JCO.2019.37.15_suppl.5542
5. A study of VB-111 with paclitaxel vs paclitaxel for treatment of recurrent platinum-resistant ovarian cancer (OVAL) (OVAL). ClinicalTrials.gov. Updated March 22, 2022. Accessed July 20, 2022. https://clinicaltrials.gov/ct2/show/NCT03398655
6. VBL Therapeutics announces positive outcome of the interim analysis in the OVAL phase 3 ovarian cancer pivotal study. News release. VBL Therapeutics. March 26, 2020. Accessed July 20, 2022. https://bit.ly/2Cm0Wfr
7. VBL Therapeutics announces second successful pre-planned interim analysis with a positive data safety monitoring committee review looking at OS – the primary endpoint of the OVAL phase 3 potential registration study of VB-111 in ovarian cancer. News release. VBL Therapeutics. August 12, 2020. Accessed July 20, 2022. https://bit.ly/2XUno6J
8. VBL Therapeutics announces data safety monitoring committee provides green light to advance the OVAL phase 3 registration enabling study of VB-111 in ovarian cancer. News release. VBL Therapeutics. February 22, 2021. Accessed July 20, 2022. https://bit.ly/3bz6LDE

This article was published by OncLive.